Cargando…

Hypertrophic cardiomyopathy: The need for randomized trials

Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition characterized by variable degrees of asymmetric left ventricular (LV) hypertrophy, generally associated with mutations in sarcomere protein genes. While generally perceived as rare, HCM is the most common genetic heart disease with ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olivotto, Iacopo, Tomberli, Benedetta, Spoladore, Roberto, Mugelli, Alessandro, Cecchi, Franco, Camici, Paolo G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bloomsbury Qatar Foundation Journals 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963756/ https://www.ncbi.nlm.nih.gov/pubmed/24689025 http://dx.doi.org/10.5339/gcsp.2013.31

Ejemplares similares

Microvascular Dysfunction in Hypertrophic Cardiomyopathy
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Clinical and molecular classification of cardiomyopathies
por: Cecchi, Franco, et al.
Publicado: (2012)

Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
por: Coppini, Raffaele, et al.
Publicado: (2014)

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
por: Bernardini, Andrea, et al.
Publicado: (2023)

Stage-specific therapy for hypertrophic cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2023)

Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Maurizi, Niccolò, et al.
Publicado: (2023)

Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions
por: Girolami, Francesca, et al.
Publicado: (2023)

Comprehensive Risk Management in Arrhythmogenic Cardiomyopathy Associated With Autosomal Dominant Carvajal Syndrome: Protecting Families
por: De Gregorio, Maria Grazia, et al.
Publicado: (2020)

Plasmatic and myocardial microRNA profiles in patients with Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2021)

Mitochondrial Energetics and Ca(2+)-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy
por: Lombardi, Maria, et al.
Publicado: (2020)

Late sodium current inhibitors to treat exercise‐induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium
por: Ferrantini, Cecilia, et al.
Publicado: (2018)

Emerging Medical Treatment for Hypertrophic Cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2021)

Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center
por: Mazzarotto, Francesco, et al.
Publicado: (2018)

Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment
por: Losi, Maria-Angela, et al.
Publicado: (2010)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
por: Palandri, Chiara, et al.
Publicado: (2022)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Late gadolinium enhancement score (LGE-Score) for prediction of extensive late gadolinium enhancement in hypertrophic cardiomyopathy
por: Chan, Raymond H, et al.
Publicado: (2015)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy
por: Foglieni, Chiara, et al.
Publicado: (2022)

Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy
por: El-Hamamsy, Ismail, et al.
Publicado: (2012)

RNA‐seq profiling reveals different pathways between remodeled vessels and myocardium in hypertrophic cardiomyopathy
por: Pisano, Annalinda, et al.
Publicado: (2022)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy
por: Finocchiaro, Gherardo, et al.
Publicado: (2017)

Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy
por: Tafelmeier, Maria, et al.
Publicado: (2020)

Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy
por: Pelliccia, F., et al.
Publicado: (2021)

Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study
por: Coppini, Raffaele, et al.
Publicado: (2019)

Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?
por: Mazzarotto, Francesco, et al.
Publicado: (2020)

Altered Ca(2+) and Na(+) Homeostasis in Human Hypertrophic Cardiomyopathy: Implications for Arrhythmogenesis
por: Coppini, Raffaele, et al.
Publicado: (2018)

Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations
por: Fioretti, Chiara, et al.
Publicado: (2020)

Report on the 2nd Florence International Symposium on Advances in Cardiomyopathies: 9th meeting of the European Myocardial and Pericardial Diseases WG of the ESC
por: Cecchi, Franco, et al.
Publicado: (2013)

Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models
por: Ferrantini, Cecilia, et al.
Publicado: (2017)

Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy
por: Velicki, Lazar, et al.
Publicado: (2020)

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
por: Ho, Carolyn Y., et al.
Publicado: (2018)

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
por: Canepa, Marco, et al.
Publicado: (2020)

Hypertrophic cardiomyopathy
por: Antunes, Murillo de Oliveira, et al.
Publicado: (2020)

Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) Instrument
por: Reaney, Matthew, et al.
Publicado: (2022)

Histopathology of the Mitral Valve Residual Leaflet in Obstructive Hypertrophic Cardiomyopathy
por: Troy, Aaron L., et al.
Publicado: (2023)

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
por: Marston, Nicholas A, et al.
Publicado: (2021)

Post-Mortem Cardiac Magnetic Resonance for the Diagnosis of Hypertrophic Cardiomyopathy
por: Aquaro, Giovanni Donato, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0djhodp5lukb5km07f2kuhsf0p